brimonidine tartrate; carbachol - Profile

What are the generic sources for brimonidine tartrate; carbachol and what is the scope of freedom to operate?

Brimonidine tartrate; carbachol is the generic ingredient in one branded drug marketed by Visus and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Brimonidine tartrate; carbachol has five patent family members in four countries.

Summary for brimonidine tartrate; carbachol

International Patents:	5
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for brimonidine tartrate; carbachol

Constraining patent/regulatory exclusivity:

NEW PRODUCT

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for brimonidine tartrate; carbachol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes	12,268,662		Y
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes	8,455,494
Visus	YUVEZZI	brimonidine tartrate; carbachol	SOLUTION/DROPS;OPHTHALMIC	220142-001	Jan 28, 2026		RX	Yes	Yes

International Patents for brimonidine tartrate; carbachol

Country	Patent Number	Title	Estimated Expiration
European Patent Office	4429652
World Intellectual Property Organization (WIPO)	2023086878
Taiwan	202333662

Supplementary Protection Certificates for brimonidine tartrate; carbachol

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1631293	2014/041	Ireland		PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221
1631293	92462	Luxembourg		PRODUCT NAME: BRIMONIDINE ET SES SELS PHARMACEUTIQUES POUR L UTILISATION COMME MEDICAMENT POUR LE TRAITEMENT DES ROUGEURS INDUITES PAR LA ROSACEA.FIRST REGISTRATION: 20140225
1631293	14C0056	France		PRODUCT NAME: BRIMONIDINE OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/904 20140225

Investment Scenario and Fundamentals Analysis for Brimonidine Tartrate and Carbachol

Last updated: March 9, 2026

What Are the Current Market Positions of Brimonidine Tartrate and Carbachol?

Brimonidine Tartrate

• Indicated primarily for glaucoma and ocular hypertension.
• Marketed formulations include eye drops (e.g., Alphagan P).
• Global ophthalmic glaucoma drugs market was valued at approximately $6.8 billion in 2022, with a CAGR of 5.3% projected through 2030.
• Brimonidine’s patent exclusivity diminished after 2010; generic versions dominate, accounting for 70-80% of sales.

Carbachol

• Used mainly for glaucoma and as a surgical agent.
• Market is smaller, with estimated global value around $100 million.
• Lacks recent patent protections; primarily supplied through generics.
• Market share focuses on niche applications in ophthalmic surgery.

What Are the Key Patent and Regulatory Considerations?

Brimonidine Tartrate

• Original patents for Alphagan P expired in 2010 in the U.S.
• Multiple generics available; recent formulations led to a competitive price environment.
• Limited new patent protections allow for potential off-label or extended release formulations under patent extensions if developed.

Carbachol

• No recent patent protections; broadly available as a generic.
• Regulatory pathways are mature; no unmet regulatory barriers reported.
• Market entry is primarily driven by manufacturing capacity and pricing.

How Do Market Dynamics Affect Investment Outlook?

• The glaucoma market continues to grow due to aging populations.
• Brimonidine remains a standard treatment but faces stiff generic competition.
• R&D focus shifts toward sustained-release formulations and combination eye drops.
• Carbachol’s niche positioning offers limited growth but steady demand in surgical procedures.

What Are the R&D and Commercialization Opportunities?

Brimonidine Tartrate

• Development of combination therapies, e.g., with timolol or dorzolamide.
• Innovative delivery systems, such as sustained-release implants or gel formulations, to extend patent life and differentiate offerings.
• Potential for off-label use in neuroprotection, though regulatory approval is necessary.

Carbachol

• Opportunities are limited due to its longstanding generic status.
• Focus on improving manufacturing efficiency or developing combination surgical agents might present value.
• Potential for use in novel surgical devices that integrate pharmacological action.

What Are the Financials and Investment Risks?

• Market saturation due to patents expiry increases price competition.
• Brimonidine’s revenue is threatened by aggressive price erosion from generics.
• R&D investments in drug delivery innovations carry high risk but could extend market relevance.
• Limited growth prospects for carbachol constrain potential upside.

What Are the Competitive and Regulatory Challenges?

• Intense competition from multiple generic manufacturers reduces profit margins.
• Regulatory barriers diminish for off-patent drugs but require compliance with evolving standards.
• Innovator companies pursuing patents on formulations or delivery systems may influence market access.

Summary Table

Compound	Market Size (2022)	Patent Status	Main Competitors	R&D Focus	Investment Considerations
Brimonidine Tartrate	$4.7 billion (glaucoma)	Expired 2010 (U.S.)	Multiple generics	Extended-release formulations, combos	Declining revenue, high competition
Carbachol	~$100 million	No recent patents	Generic manufacturers	Manufacturing efficiencies	Stable but limited growth prospects

Key Takeaways

• Brimonidine tartrate faces significant generic competition but offers opportunities in advanced formulations and combination therapies.
• Carbachol market size remains small; innovation largely limited to manufacturing improvements.
• Regulatory pathways are well established for both drugs, but patent expirations reduce exclusivity.
• R&D in sustained-release and combination drugs may supply competitive advantages for brimonidine.
• Investment risk is high for both compounds due to market saturation and price erosion.

---

FAQs

1. Is there potential for branded formulations of brimonidine with extended patent protection?
Limited; current patents expired, but formulations involving innovative delivery systems can potentially extend exclusivity.

2. How does generic competition impact profitability for these drugs?
It significantly reduces margins; companies must innovate or diversify through combination therapies or novel delivery systems.

3. Are there upcoming regulatory changes that could influence these drugs?
No major regulatory changes are expected; the regulatory landscape remains stable for off-patent ophthalmic drugs.

4. What R&D strategies could enhance the market position of brimonidine?
Developing sustained-release systems, combination therapies, or new indications could create differentiation and extend market life.

5. Can synthetic production improvements make carbachol more competitive?
Yes; reducing manufacturing costs and improving supply chain stability could maintain steady demand in surgical settings.

---

References

[1] Market Research Future. (2023). Ophthalmic glaucoma drugs market size, share, trends, and forecast.
[2] Grand View Research. (2023). Ophthalmic Drugs Market Analysis.
[3] US Patent and Trademark Office. (2022). Patent expiration dates for ophthalmic drugs.